Complement C1 Esterase Inhibitor (Human)

Introduction Overview

Generic Name

complement C1 esterase inhibitor (human)

Brand Name

Cinryze

Dosage Form

Powder for intravenous infusion after reconstitution

Drug Class

Hereditary angioedema agents

Pharmacokinetics

Absorption:
Cinryze is administered via intravenous infusion, ensuring complete bioavailability and rapid systemic availability. Since it is a plasma-derived protein replacement therapy, absorption via intravenous route bypasses gastrointestinal degradation, providing immediate therapeutic plasma concentrations. This is essential in hereditary angioedema (HAE) management to promptly replenish deficient C1 esterase inhibitor levels.

Distribution:
Post-infusion, Cinryze exhibits distribution primarily within the intravascular and extracellular fluid compartments. Given its relatively large molecular weight as a plasma protein, it does not significantly cross cellular membranes or the blood-brain barrier. The volume of distribution approximates plasma volume, reflecting its main activity in circulating plasma and mediated vascular compartments.

Metabolism:
As a human plasma-derived protein, Cinryze undergoes catabolism through proteolytic degradation by the reticuloendothelial system and target tissues. It is broken down into peptides and amino acids, which are recycled for protein synthesis. There is no hepatic enzymatic metabolism akin to small molecule drugs, and the process is not influenced by cytochrome P450 enzymes, allowing negligible drug interactions at the metabolic level.

Elimination:
Elimination of Cinryze is primarily via proteolytic catabolism and not via renal or hepatic excretion of intact drug. The estimated half-life is approximately 56 hours (range 30-80 hours), which supports its dosing interval every 3 to 4 days in prophylaxis of HAE. Clearance may be influenced by the patient’s reticuloendothelial function and disease state but no significant accumulation or dose adjustment is generally required beyond clinical monitoring.

Dosage Forms

Available Dosage Forms:
Cinryze is supplied as a sterile, lyophilized powder in single-dose vials for intravenous infusion. Each vial contains 500 units of complement C1 esterase inhibitor (human).

Dosages for Adults and Adolescents:
The standard prophylactic dose for hereditary angioedema is 1,000 units administered intravenously every 3 or 4 days. The infusion rate is typically 1 mL per minute, corresponding to dosing in a reconstituted volume of 10 mL (1,000 units/10 mL).

Specific Patient Populations:
Dosing must be individualized in pediatric patients under 18 years and in those with special clinical considerations. Safety and efficacy have been established primarily in adolescents and adults, with limited pediatric data indicating careful monitoring is advisable. Adjustments may be necessary for patients with vascular access devices or those with a history of thrombotic events. There is limited data on dose modifications during pregnancy or breastfeeding; use is advised only if clearly needed and after risk-benefit assessment.

Storage and Reconstitution:
The dry powder should be stored refrigerated or at controlled room temperature, protected from light, and not frozen. After reconstituting with the provided diluent, the solution should be used immediately or stored at room temperature and used within 3 hours. Each vial is for single use; any unused reconstituted solution must be discarded promptly.

Mechanism Of Action

Cinryze functions by supplementing the deficient or dysfunctional complement C1 esterase inhibitor (C1-INH) protein in patients with hereditary angioedema (HAE). C1-INH is a serine protease inhibitor that regulates several proteolytic cascades, primarily the classical complement pathway, the contact activation (kallikrein-kinin) system, the coagulation cascade, and fibrinolysis.

The primary molecular mechanism involves restoring physiological levels of C1-INH, which inhibits activated C1 complex proteins, preventing excessive activation of the complement system. It particularly inhibits C1r and C1s components, decreasing the formation of complement components that promote inflammation and vascular permeability.

Cinryze also acts to inhibit kallikrein-mediated cleavage of high-molecular-weight kininogen, thereby reducing excessive bradykinin formation. Bradykinin is a potent vasodilator and mediator of increased vascular permeability, responsible for the angioedema attacks seen in HAE. By limiting bradykinin production, Cinryze decreases abnormal swelling and vascular leakage.

Compared with other therapies, such as bradykinin receptor antagonists or kallikrein inhibitors, Cinryze uniquely provides a replacement approach by addressing the underlying C1-INH deficiency rather than blocking downstream mediators. Clinical studies have demonstrated that routine prophylactic administration effectively reduces frequency, severity, and duration of HAE attacks. This provides a biologically targeted therapy supported by comprehensive biochemical and clinical evidence.

Pharmacological Actions

Replacement of deficient human complement C1 esterase inhibitor protein in hereditary angioedema patients.
Inhibition of the classical complement pathway activation by blocking C1r and C1s proteases.
Suppression of the contact activation system by inhibiting kallikrein activity, reducing bradykinin production.
Regulation of intrinsic coagulation cascade and fibrinolytic pathways through protease inhibition.
Reduction of vascular permeability and edema formation in subcutaneous and submucosal tissues.
Prevention of swelling attacks and associated symptoms such as abdominal pain and airway obstruction.
Immunomodulatory effects by controlling excessive complement-mediated inflammation.
Pharmacokinetics supportive of intermittent prophylactic intravenous dosing.
Does not induce significant immunogenic or prothrombotic responses when appropriately administered.
Maintains physiological homeostasis of protease cascades involved in angioedema pathogenesis.
Unique among HAE therapies due to direct protein replacement mechanism.
Well tolerated with minimal systemic adverse effects when infused at recommended dosing.
Supports improved quality of life in chronic prophylactic management of HAE.
Lack of cytochrome P450 metabolism minimizes drug-drug interaction potential.
Clinically effective in reducing both frequency and severity of HAE episodes.

Therapeutic Or Clinical Uses

Routine prophylaxis of hereditary angioedema (HAE) attacks in adolescent and adult patients.
Prevention of acute swelling episodes in patients with C1 esterase inhibitor deficiency or dysfunction.
Management of recurrent angioedema involving subcutaneous tissues and mucosal surfaces.
Reduction of life-threatening airway obstruction episodes due to laryngeal edema in HAE.
Supportive therapy alongside on-demand treatments for acute angioedema attacks.
Treatment option for patients intolerant or unresponsive to alternative HAE therapies.
Prophylactic agent to improve patient quality of life by decreasing attack frequency.
Prevention of abdominal angioedema manifestations causing severe pain.
Use in hereditary angioedema patients with a history of frequent or severe attacks.
Part of comprehensive HAE management involving monitoring and individualized dosing.
Not indicated for treatment of acute attacks but effective in attack prevention.
Utilized in patients across a range of ages where approved and clinically appropriate.
May be used in patients with indwelling vascular catheters under medical supervision.
Option for patients seeking plasma-derived biologic with established safety profile.
Licensed treatment supported by FDA approval for specific hereditary angioedema indications.

Side Or Adverse Effects

Injection site reactions including pain, bruising, itching, swelling, bleeding, warmth, or firm lumps.
Headache, which may range from mild to moderate intensity.
Dizziness and lightheadedness reported during or after infusion.
Nausea and occasional vomiting as gastrointestinal side effects.
Mild allergic or hypersensitivity reactions such as rash or urticaria.
Stuffy nose and sore throat potentially related to infusion or immune response.
Fever or chills observed in some patients post-infusion.
Signs of serious allergic reactions including wheezing, difficulty breathing, facial swelling.
Rare risk of thromboembolic events, particularly in patients with predisposing factors.
Possible transmission risk of infectious agents despite rigorous plasma screening.
Transient elevations or abnormalities in blood pressure during or after treatment.
Fatigue or malaise reported in isolated cases.
Potential immunogenicity though clinically significant antibody formation is rare.
Local site infection risk diminished with sterile technique during intravenous administration.
Not associated with systemic coagulation abnormalities or complement activation when used properly.

Precautions

Do not use if patient has had a life-threatening allergic reaction to C1 esterase inhibitor products.
Inform healthcare providers of history of stroke, thrombosis, or cardiovascular disease prior to use.
Use caution in patients with indwelling catheters to reduce infection risk.
Pregnancy and breastfeeding status should be discussed with prescribing physician.
Cinryze contains human plasma; risk of transmitting infectious agents cannot be completely excluded.
Ensure proper training before self-administration to avoid injection errors and contamination.
Store and handle reconstituted solution according to manufacturer instructions to maintain efficacy.
Monitor patients for signs of hypersensitivity or anaphylaxis during and after infusion.
Use caution in patients receiving concomitant prothrombotic medications.
Maintain up-to-date vaccinations due to protein replacement therapy.
Avoid use in pediatric patients without specific medical guidance.
Do not exceed recommended dosing or administration frequency as per clinical protocol.
Educate patients regarding proper disposal of needles and infusion materials to prevent injury.
Monitor for signs of angioedema breakthrough and adjust dosage as clinically indicated.
Patients should have emergency medical contact available in case of adverse reactions.

Warnings

Risk of serious allergic or anaphylactic reactions; emergency medical care should be readily accessible.
Potential risk of transmission of viral and other infectious agents through plasma-derived product.
Not recommended for self-injection without adequate training and understanding of infusion technique.
Immediate discontinuation of infusion and medical evaluation required if swelling or breathing difficulties develop.
Use with caution in patients with a history of thromboembolic events; monitor for symptoms of clot formation.
Should not be administered intramuscularly or subcutaneously; intravenous route only.
Contraindicated in patients with known hypersensitivity to any ingredient of the formulation.
Do not use expired products; efficacy and safety cannot be guaranteed past expiration date.
Proper storage conditions must be maintained to preserve drug integrity and prevent loss of activity.
Infusion-related reactions such as headache or dizziness may occur and require dose adjustment.
Avoid concomitant use of procoagulant agents that may increase thrombotic risk without physician guidance.
Consider risk-benefit ratio carefully in pregnant or breastfeeding patients due to limited data.
Patients should not share medication or infusion equipment to prevent cross-contamination.
Observe patients for signs of stroke or myocardial infarction, particularly those with pre-existing conditions.
Ensure complete and effective mixing before administration; do not use if solution is discolored or contains particulates.

Contraindication

Known severe hypersensitivity or life-threatening allergic reaction to complement C1 esterase inhibitor (human) or any excipients in Cinryze.
History of anaphylactic reactions to plasma-derived preparations.
Do not use in patients with hypersensitivity to any human blood-derived products.
Contraindicated for non-intravenous routes of administration due to risk of adverse events.
Not indicated for treatment of acute hereditary angioedema attacks; usage limited to prophylaxis.
Avoid use in patients with documented clotting disorders without careful risk assessment.
Do not administer expired or improperly stored medication.
Discontinue use if signs of severe allergic reaction or angioedema unrelated to HAE develops.
Contraindicated in patients lacking intravenous access and unable to receive IV infusions safely.
Avoid in patients with active systemic infections until infections are resolved.

Drug Interactions

No significant metabolic drug interactions due to lack of cytochrome P450 involvement.
Potential pharmacodynamic interactions with other blood-derived products or anticoagulants.
Possible interaction with testosterone and anabolic steroids, which may also be used in HAE treatment.
Concomitant use with hormonal contraceptives may require monitoring due to thrombotic risk.
Limited interaction potential with over-the-counter vitamins and herbal supplements but advise disclosure.
No documented interactions with common analgesics or antihistamines used symptomatically.
Theoretical interaction with other immunomodulatory therapies necessitating clinical monitoring.
Avoid combining with agents that increase vascular permeability or inflammatory mediators.
Potential alteration of coagulation parameters when used with anticoagulants or antifibrinolytics.
No documented interaction with vaccines, but timing should be discussed with provider.
Must inform healthcare team of all medications to preempt potential overlapping side effects.
No evidence of interference with laboratory tests, but clinicians should remain vigilant.
No known interactions with dietary components or restrictions required after infusion.
Patients should report all medication use including supplements for comprehensive review.
Clinically insignificant interactions with common cardiac or antihypertensive drugs.

Preparations Of The Drug

Cinryze is marketed as lyophilized powder in single-dose vials containing 500 units of complement C1 esterase inhibitor (human).
Each vial is intended for single-use only and must be reconstituted with the supplied sterile diluent before administration.
The reconstituted solution should be clear or slightly bluish and free from particulate matter.
No preservatives are included in the formulation; aseptic technique must be observed during handling.
Packaging provides sterile, sealed vials stored refrigerated or at controlled room temperature with light protection.
Comes with detailed patient and healthcare provider instructions for safe mixing, administration, and disposal.
Supplied with diluent vial packaged separately for use during reconstitution immediately prior to infusion.
Available in 500 unit strength vials; two vials typically required for a standard prophylactic dose of 1,000 units.
Approved and manufactured under strict plasma donor screening and pathogen inactivation procedures.
Storage requirements include refrigeration (2-8°C) or controlled room temperature (up to 25°C); freezing is contraindicated.
Shelf life generally extends up to the labeled expiration date when stored properly.
Commercially produced and distributed by Takeda Pharmaceuticals U.S.A., Inc.
Requires intravenous infusion equipment for administration; infusion set and needles are not supplied.
Patient self-administration kits may be available with appropriate training and medical oversight.
Packaging includes warnings, usage guidelines, and patient support information to ensure safe use.